文献速递鼻科

联合药物治疗中重度变应性鼻炎的疗效与安全性:一项网络Meta分析

Efficacy and Safety of Combined Pharmacotherapies in Moderate-to-Severe Allergic Rhinitis: A Network Meta-Analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-03-26

本网络Meta分析纳入48项随机对照试验共17188例中重度变应性鼻炎患者,比较鼻用糖皮质激素(INCS)、鼻用抗组胺药(INAH)、口服抗组胺药(OAH)和口服白三烯受体拮抗剂(LTRA)不同联合方案的疗效与安全性。结果显示联合治疗总体优于单药治疗,INAH联合INCS在改善鼻部症状方面优势最大,但INAH和INCS联合INAH会增加总体不良事件风险,特定不良事件主要为苦味。

要点

  • 联合治疗总体疗效优于单药治疗。
  • INAH联合INCS在改善鼻部症状方面优势最大。
  • INAH和INCS联合INAH增加总体不良事件风险,特定不良事件主要为苦味。

核心结论

  • 联合治疗总体疗效优于单药治疗,INAH联合INCS在症状改善方面优势最大,若苦味不可接受,OAH联合INCS可作为可行的替代治疗选择。

研究设计与样本

  • 检索电子数据库(建库至2024年5月31日)纳入中重度变应性鼻炎联合治疗的随机对照试验,采用随机效应模型进行网络Meta分析,遵循PRISMA指南。
  • 共纳入48项符合条件的研究,17188例受试者。

主要发现

  • 在改善总鼻部症状评分方面,INAH联合INCS、OAH联合INCS和INCS最为有效。
  • 在改善总眼部症状评分方面,INAH联合INCS、INAH和INCS最为有效。
  • 在改善鼻结膜炎生活质量问卷方面,INCS联合LTRA、OAH联合INCS和INAH联合INCS获益最大。
  • INAH和INCS联合INAH增加总体不良事件风险,特定不良事件主要为苦味。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination pharmacotherapies are often selected for moderate-to-severe allergic rhinitis (AR), particularly when monotherapies do not control symptoms effectively. However, few studies have compared the efficacy and safety of different combination regimens. Therefore, we performed this study to investigate the clinical benefits of different combination strategies for moderate-to-severe AR. METHODS: Electronic databases were searched (inception-May 31, 2024) for randomized controlled trials involving combination therapies for treating moderate-to-severe AR. The medication classes included intranasal corticosteroids (INCS), intranasal antihistamines (INAH), oral antihistamines (OAH), and oral leukotriene receptor antagonists (LTRA). A network meta-analysis with a random-effects model was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: Forty-eight eligible studies with 17,188 participants were included. In this meta-analysis, INAH and INCS, OAH and INCS, and INCS were the most effective in improving Total Nasal Symptom Score, and INAH and INCS, INAH, and INCS most effectively enhanced the total ocular symptom score. INCS and LTRA, OAH and INCS, and INAH and INCS showed the greatest benefit in improving the Rhinitis Quality of Life Questionnaire. Although INCS and INAH and INAH increased the risk of overall adverse events, specific adverse events predominantly included a bitter taste. CONCLUSION: Combination therapies demonstrated superior efficacy compared to monotherapies overall. The INAH and INCS combination provided the greatest advantage in symptom improvement. The combination of OAH and INCS could be a viable alternative treatment option if the bitter taste is unacceptable. Our findings provide novel insights into optimizing personalized combination therapies.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhang Z, Wang C, et al. Efficacy and Safety of Combined Pharmacotherapies in Moderate-to-Severe Allergic Rhinitis: A Network Meta-Analysis. Int Forum Allergy Rhinol. 2025. PMID: 40135771. doi:10.1002/alr.23578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。